FIELD: medicine； pharmaceuticals.SUBSTANCE: invention relates to a compound of general formula (I) possessing the property of a P2X7 receptor inhibitor, a based pharmaceutical composition and a method for preparing such a composition, to intermediate compounds, a method of treatment and use. In general formula (I), X is N or N-oxide； n equals 0 or 1； R1 is selected from a group consisting of (1) hydrogen, (3) a hydroxyl group, (4) -NH2 and (6) -S(O)mC1-6 alkyl, where C1-6 alkyl can be substituted with hydroxyl； where m equals 2； R2 is selected from a group consisting of (1) hydrogen, (2) halogen, (3) C1-6 alkyl and (4) -OC1-6 alkyl； where C1-6 alkyl or -OC1-6 alkyl is unsubstituted or substituted with one or two substitutes independently selected from a group consisting of halogen, hydroxyl, -OC1-6 alkyl, -CN, -NR9aR10a, -(C=O)-R9a, -(C=O)-NR9aR10a and -S(O)m-R9a, where m is independently 0, 1 or 2； R1 can form with R2 group =CH2 or =O； or R1 can form with R2 5–6-member ring which can contain from one to three heteroatoms independently selected from a group consisting of a nitrogen atom, an oxygen atom and a carbonyl group； where 5–6 member ring is unsubstituted or substituted with one C1-6 alkyl； R3 is independently selected from a group consisting of (2) halogen and (3) C1-6 alkyl； p is 0 or 1； R4 is selected from a group consisting of (1) hydrogen, (2) halogen and (3) a hydroxyl group； R5 denotes hydrogen or C1-6 alkyl； R6 is (1) hydrogen； R5 can form saturated 5-member ring with R6； or can form with R6a saturated or unsaturated 9–10-member bicyclic ring which can contain an oxygen atom； where saturated 5-member ring or a saturated or unsaturated bicyclic 9–10-member ring is optionally substituted with 1–3 substitutes selected from a group consisting of (2) halogen and (4) -OC1-6-alkylphenyl； R7a and R7b are independently selected from a group consisting of (1) hydrogen, (4) C1-6 alkyl and (5) -NR9bR10b； rest values of radicals are as specified in the claim..EFFE
